Related Experiment Video

Updated: May 24, 2026

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

[Chorea, lupus and antiphospholipid antibodies]

P Reiner1, J-C Piette, G Leroux

  • 1Service de neurologie, hôpital Lariboisière, université Paris-7, AP-HP, 75475 Paris cedex 10, France.

La Revue De Medecine Interne
|February 28, 2012
PubMed

Insights

Chorea in Systemic Lupus Erythematosus (SLE) is linked to antiphospholipid antibodies and may increase the risk of future blood clots. Early treatment with antiplatelet agents and hydroxychloroquine can help manage symptoms and reduce risks.

Area of Science:

  • Neurology
  • Rheumatology
  • Immunology

Context:

  • Chorea is a neurological complication observed in patients with Systemic Lupus Erythematosus (SLE).
  • The incidence of chorea in SLE ranges from 1-3% in adults and up to 9% in pediatric lupus patients.
  • Chorea often presents as an initial symptom and is strongly associated with antiphospholipid antibodies.

Purpose:

  • To investigate the clinical characteristics, treatment, and long-term risks associated with chorea in SLE patients.
  • To evaluate the relationship between chorea, antiphospholipid antibodies, and subsequent thrombotic events.
  • To assess the impact of management strategies, including antiplatelet agents, on patient outcomes.

Summary:

  • Chorea in SLE is frequently linked to antiphospholipid antibodies.
  • Standard treatment typically involves antiplatelet agents and hydroxychloroquine.
  • Patients with SLE-associated chorea face elevated risks of arterial thrombotic events, obstetric complications, and valvular disease.

Impact:

  • Identifying patients with SLE-related chorea is crucial for risk stratification.
  • Proactive management, particularly with antiplatelet therapy and careful obstetric care, may mitigate serious complications.
  • This highlights the importance of comprehensive monitoring for thrombotic and other risks in SLE patients presenting with chorea.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...